vTv Therapeutics (VTVT) Competitors $16.01 +1.11 (+7.45%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$15.93 -0.08 (-0.50%) As of 07/8/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT vs. CTMX, OGI, GNFT, FDMT, IPHA, VTYX, DERM, PBYI, DMAC, and SPROShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. Its Competitors CytomX Therapeutics Organigram Global GENFIT 4D Molecular Therapeutics Innate Pharma Ventyx Biosciences Journey Medical Puma Biotechnology DiaMedica Therapeutics Spero Therapeutics CytomX Therapeutics (NASDAQ:CTMX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk. Which has more risk and volatility, CTMX or VTVT? CytomX Therapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Is CTMX or VTVT more profitable? CytomX Therapeutics has a net margin of 28.22% compared to vTv Therapeutics' net margin of 0.00%. vTv Therapeutics' return on equity of -121.46% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics28.22% -553.71% 32.21% vTv Therapeutics N/A -121.46%-46.75% Which has preferable earnings & valuation, CTMX or VTVT? CytomX Therapeutics has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M1.40$31.87M$0.485.00vTv Therapeutics$1.02M50.07-$18.46M-$3.01-5.32 Does the media refer more to CTMX or VTVT? In the previous week, CytomX Therapeutics had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 2 mentions for CytomX Therapeutics and 0 mentions for vTv Therapeutics. CytomX Therapeutics' average media sentiment score of 0.00 equaled vTv Therapeutics'average media sentiment score. Company Overall Sentiment CytomX Therapeutics Neutral vTv Therapeutics Neutral Do analysts rate CTMX or VTVT? CytomX Therapeutics currently has a consensus target price of $5.33, suggesting a potential upside of 122.22%. vTv Therapeutics has a consensus target price of $35.50, suggesting a potential upside of 121.74%. Given CytomX Therapeutics' higher possible upside, research analysts plainly believe CytomX Therapeutics is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of CTMX or VTVT? 67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 1.3% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryCytomX Therapeutics beats vTv Therapeutics on 12 of the 14 factors compared between the two stocks. Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.60M$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-5.3220.8026.9720.11Price / Sales50.07286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book3.577.487.985.56Net Income-$18.46M-$55.04M$3.16B$248.40M7 Day Performance6.31%2.44%2.36%4.67%1 Month Performance-0.56%1.90%2.15%6.64%1 Year Performance-20.39%4.35%33.78%21.31% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics1.9833 of 5 stars$16.01+7.4%$35.50+121.7%-11.5%$47.60M$1.02M-5.329CTMXCytomX Therapeutics3.9205 of 5 stars$2.27+0.9%$5.33+134.9%+84.6%$181.40M$138.10M4.73170OGIOrganigram Global0.9599 of 5 stars$1.35flatN/A-8.9%$180.82M$117.47M13.50860News CoverageGap DownGNFTGENFIT1.5111 of 5 stars$3.73+3.2%$13.00+249.0%-15.4%$180.49M$67.00M0.00120News CoveragePositive NewsGap UpFDMT4D Molecular Therapeutics2.2773 of 5 stars$3.71-3.4%$29.56+696.6%-80.4%$177.89M$40K-1.17120IPHAInnate Pharma2.5326 of 5 stars$1.82-1.9%$11.00+506.1%-18.6%$170.53M$21.77M0.00220Positive NewsGap DownVTYXVentyx Biosciences2.3679 of 5 stars$2.14-8.5%$10.00+367.3%-9.2%$166.52MN/A-1.2230DERMJourney Medical1.8438 of 5 stars$7.18+0.6%$9.50+32.3%+21.6%$166.33M$56.13M-18.4190Analyst DowngradePBYIPuma Biotechnology3.9063 of 5 stars$3.43+3.0%$7.00+104.1%+20.5%$165.27M$230.50M4.45200DMACDiaMedica Therapeutics0.8811 of 5 stars$3.90+1.6%$8.00+105.1%+18.1%$164.67MN/A-6.0920SPROSpero Therapeutics3.8801 of 5 stars$2.90-1.4%$5.00+72.4%+131.5%$164.38M$47.98M-2.27150 Related Companies and Tools Related Companies CTMX Alternatives OGI Alternatives GNFT Alternatives FDMT Alternatives IPHA Alternatives VTYX Alternatives DERM Alternatives PBYI Alternatives DMAC Alternatives SPRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTVT) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
